Baxter, Takeda in influenza deal in Japan

Baxter International Inc. (NYSE:BAX) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive rights in Japan to use its Vero cell culture technology to develop influenza vaccines. The companies also plan to co-develop an H5N1 influenza vaccine in Japan. Baxter will receive upfront payments and development cost reimbursements and will be eligible for milestones and royalties. Further terms were not disclosed. ...